Cyn3rgy
  • Home
  • About
    • Getting Involved >
      • ONYCHOMYCOSIS OF THE TOENAIL FUNGUS
      • SCABIES
      • ACNE_landing
      • ADHD
      • SKIN STRUCTURAL INFECTIONS
      • CONSTIPATION
      • ATOPIC DERMATITIS
      • MOLLUSCUM CONTAGIOSUM
      • OVERACTIVE BLADDER
      • MENINGOCOCCAL
      • PNEUMOCOCCAL DISEASE
      • DIAGNOSTIC SAMPLE STUDIES
      • CORONAVIRUS CLINICAL TRIALS
  • Contact
  • Privacy Policy
Picture
Study 1: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis.

Study 2: A Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable.


 For more information, call
Cyn3rgy Research at
​503 907 2179 x3
Sign Up for one of our studies!
    Your email will not be shared with any other companies. 
Submit

We Would Love to hear from you!

Hours

Address:Cyn3rgy Research
24850 SE Stark St. Suite #180
Gresham, OR 97030

Business Hours: Due to the COVID 19 outbreak in our community, Cyn3rgy Research is open, but operating on amended hours for the time being. Until further notice, Cyn3rgy’s operating hours are as follows;
Mon – Thursday, 8:00 am – 5:30 pm
Fri - Per scheduled appointment. 

Telephone

503-907-2179



Email

support@cyn3rgy.com
  • Home
  • About
    • Getting Involved >
      • ONYCHOMYCOSIS OF THE TOENAIL FUNGUS
      • SCABIES
      • ACNE_landing
      • ADHD
      • SKIN STRUCTURAL INFECTIONS
      • CONSTIPATION
      • ATOPIC DERMATITIS
      • MOLLUSCUM CONTAGIOSUM
      • OVERACTIVE BLADDER
      • MENINGOCOCCAL
      • PNEUMOCOCCAL DISEASE
      • DIAGNOSTIC SAMPLE STUDIES
      • CORONAVIRUS CLINICAL TRIALS
  • Contact
  • Privacy Policy